Response of factor V inhibitor to rituximab in a patient who received liver transplantation for primary biliary cirrhosis

Eric Chun Yet Lian, Andreas G. Tzakis, David Andrews

Research output: Contribution to journalArticle

24 Scopus citations


A 43-year-old patient developed factor V inhibitor 6 months after liver transplantation for primary biliary cirrhosis in association with Sjögren's syndrome/systemic lupus erythematosus. She suffered from ecchymoses in the lower extremities. The factor V inhibitor was eradicated after 10 weekly doses of 375-500 mg/m2 rituximab.

Original languageEnglish (US)
Pages (from-to)363-365
Number of pages3
JournalAmerican Journal of Hematology
Issue number4
StatePublished - Dec 1 2004



  • Factor V inhibitor
  • Primary biliary cirrhosis
  • Rituximab
  • Sjögren's syndrome
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Hematology

Cite this